Endoscopic Retrograde Cholangiopancreatography Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Endoscopic Retrograde Cholangiopancreatography Market is projected to expand from a valuation of USD 2.23 Billion in 2025 to USD 3.69 Billion by 2031, reflecting a compound annual growth rate of 8.76%. As a specialized medical intervention, Endoscopic Retrograde Cholangiopancreatography integrates upper gastrointestinal endoscopy with radiographic imaging to address pathologies within the pancreatic and bile ducts. This market trajectory is primarily propelled by an aging global demographic and an increasing incidence of biliary disorders, factors that necessitate therapeutic measures and sustain the demand for efficient diagnostic and treatment solutions, thereby underpinning the sector's financial progress.

Conversely, the industry confronts a significant obstacle regarding the limited availability of physicians possessing the expertise to safely execute this intricate procedure. This shortage of skilled professionals threatens to create service bottlenecks and restrict the volume of procedures, particularly within emerging markets. Data from the American Cancer Society indicates that approximately 67,440 individuals in the United States will receive a pancreatic cancer diagnosis in 2025, a statistic that underscores the urgent need for these interventions. Consequently, the persistent burden of disease remains a critical factor fueling the continued utilization of endoscopic solutions despite workforce constraints.

Market Drivers

The increasing implementation of single-use duodenoscopes is significantly reshaping the market as healthcare facilities emphasize infection prevention and operational efficiency to eliminate cross-contamination risks linked to reusable instruments. This shift is accelerated by regulatory guidance and the economic advantages of discarding complex reprocessing procedures, which lowers the overall cost of ownership for hospitals. According to the 'Annual Report 2024/25' published by Ambu A/S in November 2025, the company achieved an organic growth rate of 15.4 percent within its Endoscopy Solutions division, a figure that highlights the rapid transition toward disposable technologies as institutions upgrade legacy equipment to improve patient safety.

Additionally, the rising incidence of biliary and pancreatic conditions acts as the central clinical force increasing the global volume of endoscopic procedures. Factors such as lifestyle shifts and an aging population are leading to higher rates of malignancies and gallstones, requiring accurate therapeutic and diagnostic interventions. As noted by the National Institutes of Health in the February 2025 article 'Trends in the Global Incidence of Pancreatic Cancer', the global disease burden involved an estimated 510,922 new cases in the 2022 reference year, with forecasts suggesting a continuing rise. This epidemiological trend drives manufacturers to expand capabilities, reflected in Boston Scientific's 2025 report of 16.75 billion dollars in full-year 2024 net sales, a 17.6 percent increase attributed to strong medical and surgical portfolio performance.

Market Challenges

A primary hurdle facing the Global Endoscopic Retrograde Cholangiopancreatography Market is the shortage of medical professionals qualified to perform ERCP procedures. Because this technique demands extensive specialized training and a high degree of technical skill, the number of capable practitioners remains limited. As the incidence of pancreatic and biliary disorders grows, the inability of healthcare infrastructures to expand their workforce proportionally creates severe bottlenecks. These deficiencies result in extended patient wait times and diminished procedure volumes, factors that directly impede the market's revenue generation capabilities.

Moreover, the steep learning curve required for ERCP dissuades many emerging physicians from pursuing this specialty, placing further strain on the current workforce. This pressure is compounded by demographic changes within the medical community itself. According to the Association of American Medical Colleges, the United States healthcare system was projected in 2024 to encounter a physician shortage of up to 86,000 by 2036, a deficit that critically affects complex fields such as gastroenterology. This growing disparity between the demand for therapeutic interventions and the supply of skilled endoscopists limits market growth, particularly in developing and underserved areas where educational infrastructure is already sparse.

Market Trends

The incorporation of artificial intelligence into image analysis is emerging as a transformative element in the ERCP sector, significantly improving procedural decision-making and diagnostic accuracy. These sophisticated algorithms assist endoscopists in differentiating indeterminate strictures and detecting biliary lesions in real-time, thereby minimizing the inter-observer variability inherent in conventional fluoroscopic interpretation. Beyond diagnostics, this technology is evolving to forecast post-procedure complications, facilitating more tailored patient care. In a January 2025 national survey report on digital health trends, the American Medical Association noted that 66 percent of physicians employed artificial intelligence tools in 2024, a 78 percent increase from the prior year that illustrates the rapid adoption of data-driven solutions in gastroenterology.

Concurrently, the market is experiencing significant progress in high-definition visualization systems and digital cholangioscopy. This trend represents a major shift away from indirect radiographic imaging, enabling clinicians to obtain clear, direct views of the pancreatic and bile ducts for complex lithotripsy and precise biopsies. The escalating clinical demand for these advanced optical platforms stems from the need to manage difficult stone burdens and accurately stage malignancies without resorting to repeated procedures. Evidence of this demand is found in Olympus Corporation’s 'Consolidated Financial Results for the Six Months Ended September 30, 2024', released in November 2024, which reported a 10.3 percent revenue increase in its Endoscopic Solutions Business, driven largely by strong sales of advanced visualization systems in Europe and North America.

Key Players Profiled in the Endoscopic Retrograde Cholangiopancreatography Market

• Olympus Corporation
• CONMED Corporation
• Boston Scientific Corporation
• Medtronic PLC
• TeleMed Systems, Inc.
• Ambu A/S
• FUJIFILM Holdings Corporation
• HOBBS MEDICAL INC.
• Cook Group Incorporated
• HOYA Corporation

Report Scope

In this report, the Global Endoscopic Retrograde Cholangiopancreatography Market has been segmented into the following categories:

Endoscopic Retrograde Cholangiopancreatography Market, by Product:

• Endoscopes
• Endotherapy Devices
• Visualization Systems
• Energy Devices
• Others

Endoscopic Retrograde Cholangiopancreatography Market, by Procedure:

• Biliary Sphincterotomy
• Biliary Stenting
• Biliary Dilatation
• Pancreatic Sphincterotomy
• Pancreatic Duct Stenting
• Pancreatic Duct Dilation

Endoscopic Retrograde Cholangiopancreatography Market, by End User:

• Hospitals
• Outpatient Facilities

Endoscopic Retrograde Cholangiopancreatography Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Endoscopic Retrograde Cholangiopancreatography Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.